|
|
|
市場調査レポート
癌治療におけるモノクローナル抗体：2009〜2024年
Monoclonal Antibodies in Cancer Therapy 2009-2024
| 発行 |
Visiongain |
| 出版日 |
2009年05月 |
商品コード |
92343 |
| ページ情報 |
英文 97 pages |
| 価格 |
|
|
Abstract
Report Details
Monoclonal antibodies in cancer therapy - significant commercial
opportunities with developing technologies and innovative products - our new
report explains prospects
Monoclonal antibody-based therapies for cancer are a thriving part of the
biotechnology sector, as our new market report explains. The oncology market
continues to expand worldwide, with high demand for more-efficacious and
better-tolerated cancer therapies. The monoclonal antibodies oncology market
has been growing at a significant rate and holds high potential for continued
growth in both developed and emerging geographical markets. Currently, new
technologies are removing some of the drawbacks that monoclonal antibody
therapies have experienced. Leading pharma companies are already investing
heavily in monoclonal antibody technologies. Monoclonal antibodies with great
commercial potential are in the oncology pipeline, as our new report -
Monoclonal Antibodies in Cancer Therapy 2009-2024 - also explains.
The period 2009 to 2019 will reveal volatility in the monoclonal antibody
therapies market as current-leading products reach peak sales and
new-generation drugs emerge. Will technological advances further benefit
monoclonal antibody-based therapies and their overall sales? Will better
immunotoxicity profiles lead to higher revenues for products? What types of
monoclonal antibody therapies will enter the market from 2009 onwards, and can
they dominate this market? Where will the opportunities lie, and what are the
market drivers and restraints? This report will provide you with the
information that you need to understand current trends and future
possibilities. In particular, we discuss prospects for the following
products:
- Rituxan
- Avastin
- Herceptin
- Erbitux
- Vectibix
- Campath.
Comprehensive analysis of this important market area
Monoclonal Antibodies in Cancer Therapy 2009-2024 examines that market sector
critically, through a comprehensive review of information sources, including
consultations with relevant experts. This report provides detailed sales
forecasts, discussions of pipeline developments and analysis of commercial
drivers and restraints, including a SWOT analysis. There are over 55 tables
and figures included. The result is a comprehensive market- and
industry-centred report with detailed analyses and informed opinion.
Why you should buy this report
Benefits that you will gain from Monoclonal Antibodies in Cancer Therapy
2009-2024 include:
- Appraisal of the existing market for monoclonal antibody cancer therapies
- Forecasting and discussion of market values for monoclonal antibody cancer
therapies, including detailed sales forecasts for 2009 to 2024
- Discussion of leading products, including sales forecasts, growth and
market share analyses
- Analyses of 10 leading national markets for monoclonal antibody cancer
therapies, including China and India, with forecasted sales and market shares
- Coverage of R&D pipeline developments, with trends to watch out for
- Exclusive interviews with a leading academic and mAbs journal chief editor
and with a chief scientist in oncology within a leading pharma company
- Informed analyses of strengths and weaknesses of the technologies from
2009 onwards
- Balanced assessments of commercial drivers and restraints that the market
area faces from 2009 to 2024.
Nobody with a commercial interest in biotechnology or in cancer therapies can
afford to overlook this new study from visiongain. The market environment in
many countries will change. There will also be further development of the
Chinese and Indian biotechnology sectors - especially relevant from next
decade onwards. Importantly, there will be increases in demand in both
developed and developing national markets. With an impressive R&D pipeline,
this area holds great potential for new products. Do you want to know more
about this important market?
Table of Contents
1. Executive Summary
- 1.1 Aims of this Report
- 1.2 Brief Overview of the Chapters in this Report
2. Monoclonal Antibodies for Cancer Therapy
- 2.1 Oncology is the Fifth-Largest Therapeutic Class Worldwide by Total
Sales
- 2.2 The Oncology Market is Expanding
- 2.3 Monoclonal Antibodies
- 2.3.1 What are Monoclonal Antibodies?
- 2.3.2 How do Monoclonal Antibody Therapies Work?
- 2.4 Categories of Monoclonal Antibodies for Therapeutic Use
- 2.4.1 Murine Antibodies
- 2.4.2 Chimeric and Humanised Antibodies
- 2.4.3 Human Antibodies
- 2.4.4 Immunogenicity
- 2.5 Current Monoclonal Antibody Cancer Therapies
- 2.5.1 Rituxan/MabThera
- 2.5.2 Avastin
- 2.5.3 Herceptin
- 2.5.4 Erbitux
- 2.5.5 Vectibix
- 2.5.6 Campath
- 2.5.7 Mylotarg
- 2.5.8 Zevalin and Bexxar
- 2.5.9 The Market Shares of Naked vs. Conjugated Monoclonal Antibodies
- 2.5.10 The Market for Monoclonal Antibody Therapies is Growing.
3. Total World Market 2009-2024
- 3.1 Summary of Key Findings
- 3.2 Biotech is a Rapidly-Expanding Market
- 3.3 Monoclonal Antibodies are a Central Part of the Biotech Market
- 3.4 Oncology - A Major Sales Driver in the Mab Sector
- 3.5 Total World Market in 2008
- 3.6 Predicted Sales from 2009-2024
- 3.7 The Big Three
- 3.8 Generic Competition
- 3.9 Chimeric Antibodies in Decline
- 3.10 The Shift Towards Human Antibodies
4. Key Products Analysis
- 4.1 Overview: Strong Pipeline Means Competition Will Increase
- 4.2 Roche/Genentech Dominated the Market in 2008
- 4.3 Rituxan/MabThera (Roche/Genentech)
- 4.3.1 Will Rituxan Continue Steady Growth over the Next Five Years?
- 4.4 Avastin (Roche/Genentech)
- 4.4.1 Broadened Profile and Patient Base
- 4.4.2 Continued Growth Despite Competition
- 4.5 Herceptin (Roche/Genentech)
- 4.5.1 Strong Competition in the R&D Pipeline
- 4.6 Erbitux (Merck/Imclone)
- 4.6.1 Aiming for the Top Three
- 4.7 Vectibix (Amgen)
- 4.8 Campath (Bayer Schering AG)
- 4.8.1 Future Increase in Revenue?
5. SWOT Analysis for the Monoclonal Antibody Oncology Therapies Market
- 5.1 Principal Drivers
- 5.1.1 Increasing Prevalence and High Economic Costs of Cancer
- 5.1.2 MAb Therapy Presents Lower Risk of Adverse Effects
- 5.1.3 Combining Existing Products
- 5.1.4 Biologicals vs. Chemically-Derived Pharmaceutical Products
- 5.1.5 Promising Pipelines
- 5.1.6 Improvements in Accessibility
- 5.1.7 New Production Methods will Reduce Costs
- 5.2 Principal Restraints
- 5.2.1 Development Costs - a High Barrier of Entry
- 5.2.2 Mode of Administration is a Limiting Factor
- 5.2.3 Insufficient Efficacy as a Single Agent
- 5.2.4 Immunogenicity - the Rise of Humanised and Human Monoclonal
Antibodies
- 5.2.5 Financial Limitations in Research and Development
- 5.2.6 Adverse Events - Safety Concerns
- 5.2.7 Competition for Prime Drug Targets
6. MAbs in the Leading Pharmaceutical Markets
- 6.1 USA
- 6.2 Europe
- 6.3 Other Countries
7. The Monoclonal Antibody Cancer Therapies Pipeline
- 7.1 New Technology - Monoclonal Antibody Fragments
- 7.1.1 Bispecific T-Cell Engagers
- 7.1.2 Tandabs
- 7.2 Conjugated vs. Naked Antibodies
- 7.3 The Future of Human MAbs
- 7.4 Competition for Prime Drug Targets
- 7.5 Solid Pipeline
- 7.6 Products to Watch
- 7.6.1 Roche' s Winning Pipeline
- 7.6.2 Genmab and GlaxoSmithKline' s Arzerra/HuMax-CD20
- 7.6.3 Amgen' s AMG 162
8. Visiongain Interviews with Relevant Experts
- 8.1 Dr Janice M. Reichert, Tufts University and Editor-in-Chief of the
Journal mAbs
- 8.1.1 Major Challenges and Opportunities for Monoclonal Antibody Cancer
Therapies
- 8.1.2 Future Developments and Pipelines
- 8.1.3 The Effect of Biosimilars
- 8.2 Dr David Blakey, AstraZeneca
- 8.2.1 The Future of Humanised and Fully-Human Antibodies
- 8.2.2 Therapeutic Antibody Fragments vs. Full-Length IgGs
- 8.2.3 Major Opportunities in Monoclonal Antibody Cancer Therapies
9. Conclusions
- 9.1 The MAb Market is Strong and Expected to Grow Stronger
- 9.2 Expansion into New Markets
- 9.3 Personalised Treatments Emerging
- 9.4 Growth Will Eventually Slow as Expansion of the Market Drives Prices
Down
- 9.5 Outlook for the Future
List of Tables
- Table 2.1 Summary of Types of Monoclonal Antibodies for Cancer Therapy
- Table 2.2 Targets and Indications for Selected FDA-Approved Antibodies
- Table 3.1 Top Selling FDA Approved Antibodies, 2008
- Table 3.2 Leading Monoclonal Antibodies for Oncology Therapies, Sales
($bn) and Market Shares (%), 2008
- Table 3.3 Predicted Sales ($bn) for the World Market, 2009-2024
- Table 3.4 Predicted Growth Rate (%) for the World Market, 2009-2024
- Table 3.5 World Sales ($bn) and Market Shares (%) for the Different Types
of Oncology Monoclonal Antibodies, 2008
- Table 3.6 Market Shares (%) for Chimeric, Humanised and Human Monoclonal
Antibodies, 2014-2024
- Table 4.1 Predicted Sales ($bn) for the World Market, 2009-2016
- Table 4.2 Predicted Sales ($bn) for the World Market, 2017-2024
- Table 4.3 Market Shares (%) and CAGR (%) for Selected Products, 2008 and
2014
- Table 5.1 SWOT Analysis, 2009-2024
- Table 5.2 Side Effects of Monoclonal Antibody Therapy
- Table 6.1 Leading Regions of the Monoclonal Antibody Anticancer Therapies
Market, Sales ($bn) and Market Shares (%), 2008 and 2014
- Table 7.1 Selected Phase III and Pre-Registration Anticancer Monoclonal
Antibodies, 2008
- Table 9.1 Global Monoclonal Antibody Anticancer Therapies, Sales ($bn) and
Growth (%), 2008-2014
List of Figures
- Figure 2.1 Sales ($bn) of Naked vs. Conjugated Monoclonal Antibodies, 2008
- Figure 3.1 Market Shares (%) for the Main Categories of the Monoclonal
Antibody Market for 12 Months up to Q3 2008
- Figure 3.2 Sales ($bn) for the Top Three Monoclonal Antibody Oncology
Therapies, 2005-2008
- Figure 3.3 Sales ($bn) for Monoclonal Antibody Oncology Therapies for 12
Months up to Q3 2008
- Figure 3.4 Market Shares (%) for Monoclonal Antibody Oncology Therapies
for 12 Months up to Q3 2008
- Figure 3.5 Predicted Sales ($bn) for the World Market, 2009-2024
- Figure 3.6 Predicted Growth (%) of the World Market, 2009-2014
- Figure 3.7 Predicted Sales ($bn) for the Big Three: Rituxan, Avastin and
Herceptin, 2009-2014
- Figure 3.8 Sales ($bn) for Different Types of Monoclonal Antibodies for
Oncology, 2008
- Figure 3.9 Market Shares (%) for Different Types of Monoclonal Antibodies
for Oncology, 2008
- Figure 3.10 Pipeline Drugs (Phase II and III) by Antibody Type, 2008
- Figure 3.11 Predicted Market Shares (%) for Chimeric, Humanised and Human
Monoclonal Antibodies, 2014-2024
- Figure 4.1 Market Shares (%) for Companies in the Monoclonal Antibody
Oncology Therapies Area, 2008
- Figure 4.2 Sales ($bn) for Rituxan, 2005-2008
- Figure 4.3 Sales ($bn) for Rituxan, 2009-2014
- Figure 4.4 Market Share (%) for Rituxan, 2009-2014
- Figure 4.5 Sales ($bn) for Rituxan/MabThera, 2009-2024
- Figure 4.6 Sales ($bn) for Avastin and Rituxan, 2009-2024
- Figure 4.7 Sales ($bn) for Avastin, 2005-2008
- Figure 4.8 Market Share (%) for Avastin, 2009-2014
- Figure 4.9 Sales ($bn) for Avastin, 2009-2024
- Figure 4.10 Sales ($bn) for Herceptin, 2005-2008
- Figure 4.11 Sales ($bn) for Herceptin, 2009-2024
- Figure 4.12 Market Share (%) for Herceptin, 2008-2014
- Figure 4.13 Sales ($bn) for Erbitux, 2005-2008
- Figure 4.14 Sales ($bn) for Erbitux, Herceptin and Rituxan, 2009-2024
- Figure 4.15 Sales ($bn) for Erbitux, 2009-2024
- Figure 4.16 Market Share (%) for Erbitux, 2009-2014
- Figure 4.17 Sales ($bn) for Vectibix, 2009-2014
- Figure 4.18 Market Share (%) for Vectibix, 2009-2014
- Figure 4.19 Sales ($bn) for Vectibix, 2009-2024
- Figure 4.20 Sales ($bn) for Campath, 2005-2008
- Figure 4.21 Sales ($bn) for Campath, 2009-2024
- Figure 4.22 Market Share (%) for Campath, 2009-2014
- Figure 6.1 Leading Pharmaceutical Markets, Sales ($bn), 2008, 2014, 2019
and 2024
- Figure 6.2 Leading Pharmaceutical Markets, Market Shares (%), 2008, 2014,
2019 and 2024
- Figure 6.3 Leading Pharmaceutical Markets, CAGR (%), 2008-2014
- Figure 6.4 Comparisons of the US, European, Chinese and Indian Markets,
Market Shares (%), 2008-2024
- Figure 7.1 Pipeline Drugs (Phase II) by Indication, 2008
- Figure 7.2 Pipeline Drugs (Phase III) by Indication, 2008
Companies Listed
- Abbott Laboratories
- Affimed Therapeutics
- AstraZeneca
- American Cancer Society
- Amgen
- Bayer Schering Pharma
- Biogen-Idec
- Bradmer Pharmaceuticals
- Bristol-Myers Squibb
- Dr. Reddy' s Laboratories
- Elan Pharmaceuticals
- Eli Lilly
- Esteve
- EMEA
- Fresenius SE
- Genentech
- Genmab
- Genzyme (ILEX Oncology)
- GlaxoSmithKline
- GlycArt Biotechnology
- ImClone Systems
- International Agency for Research on Cancer
- Johnson & Johnson
- Menarini Merck & Co.
- Micromet
- Millennium Pharmaceuticals
- Novartis
- Paladin Labs
- Pfizer
- Roche
- TeGenero
- Trion Pharma
- Tufts University
- US FDA
- Viventia Biotech
- World Health Organisation
- Wilex
- Wyeth Pharmaceuticals
|
 |
